Background
Phase 3, open-label, randomized controlled trial (ASC4FIRST). N=405 patients with newly diagnosed Ph+ chronic-phase CML. Randomized 1:1 to asciminib vs investigator's choice (IC) TKI (imatinib 400 mg, nilotinib 300 mg BID, dasatinib 100 mg QD, or bosutinib 400 mg QD), with prestratification by investigator-selected TKI. Asciminib is a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket) — the first-in-class allosteric BCR-ABL1 inhibitor with a distinct binding mechanism from ATP-competitive TKIs and minimal off-target kinase inhibition.
Interventions and follow up
Arm A: Asciminib 80 mg PO once daily until progression or unacceptable toxicity
Arm B: Investigator's choice TKI (imatinib 400 mg QD, nilotinib 300 mg BID, dasatinib 100 mg QD, or bosutinib 400 mg QD) until progression or unacceptable toxicity
Primary endpoint: MMR (BCR-ABL IS ≤0.1%) at 48 weeks (vs all IC-TKI; and vs imatinib stratum)
mFollow up: 48 weeks (primary analysis)
Arm B: Investigator's choice TKI (imatinib 400 mg QD, nilotinib 300 mg BID, dasatinib 100 mg QD, or bosutinib 400 mg QD) until progression or unacceptable toxicity
Primary endpoint: MMR (BCR-ABL IS ≤0.1%) at 48 weeks (vs all IC-TKI; and vs imatinib stratum)
mFollow up: 48 weeks (primary analysis)
Results
MMR at 48 weeks (vs all IC-TKI): 67.7% (asciminib) vs 49.0% (IC-TKI), P<.001
MMR at 48 weeks (vs imatinib stratum): 69.3% (asciminib) vs 40.2% (imatinib), P<.001
MMR at 48 weeks (vs 2G-TKI stratum): 66.0% vs 57.8% (not formally significant)
CMR4 (BCR-ABL ≤0.01%) at 48 weeks: ~39% vs ~21%
CMR4.5 (BCR-ABL ≤0.0032%) at 48 weeks: ~28% vs ~10%
MMR at 48 weeks (vs imatinib stratum): 69.3% (asciminib) vs 40.2% (imatinib), P<.001
MMR at 48 weeks (vs 2G-TKI stratum): 66.0% vs 57.8% (not formally significant)
CMR4 (BCR-ABL ≤0.01%) at 48 weeks: ~39% vs ~21%
CMR4.5 (BCR-ABL ≤0.0032%) at 48 weeks: ~28% vs ~10%
Adverse events
Hematologic: Thrombocytopenia grade ≥3 ~7.5% (asciminib) vs ~3% (IC-TKI); neutropenia grade ≥3 lower than with 2G-TKI comparators
Cardiovascular/Other: Hypertension grade ≥3 7.5% vs 1.6%; arterial occlusive events any grade 3.7% (asciminib) vs 0%; musculoskeletal pain any grade ~20.9%
Tolerability: Grade ≥3 AEs 37.3% vs 44.8%; discontinuation due to AEs 5.2% (asciminib) vs 14.1% (IC-TKI) — markedly lower with asciminib
Cardiovascular/Other: Hypertension grade ≥3 7.5% vs 1.6%; arterial occlusive events any grade 3.7% (asciminib) vs 0%; musculoskeletal pain any grade ~20.9%
Tolerability: Grade ≥3 AEs 37.3% vs 44.8%; discontinuation due to AEs 5.2% (asciminib) vs 14.1% (IC-TKI) — markedly lower with asciminib
Conclusions
Asciminib significantly improved MMR at 48 weeks versus investigator's choice TKI in newly diagnosed CP-CML (67.7% vs 49.0%, P<.001) and versus imatinib specifically, with deeper molecular responses and markedly lower discontinuation due to AEs, supporting it as a new frontline option.
Key Limitations
Composite comparator: Asciminib was statistically superior to imatinib but only numerically better than the 2G-TKI stratum, which was not formally significant
Short follow-up: 48-week primary analysis; long-term PFS, OS, and treatment-free remission data are awaited
Open-label: Investigator-selected comparator introduces potential bias; arterial occlusive events occurred only in the asciminib arm, requiring cardiovascular monitoring
Short follow-up: 48-week primary analysis; long-term PFS, OS, and treatment-free remission data are awaited
Open-label: Investigator-selected comparator introduces potential bias; arterial occlusive events occurred only in the asciminib arm, requiring cardiovascular monitoring
Clinical Context
ASC4FIRST supported FDA approval of asciminib for newly diagnosed Ph+ CP-CML (label expansion, 2024) — the first frontline approval for a STAMP inhibitor. Asciminib joins imatinib, nilotinib, dasatinib, and bosutinib as frontline options; its allosteric mechanism avoids many resistance mutations that confer cross-resistance among ATP-competitive TKIs. Asciminib 80 mg QD is the frontline dose; 200 mg BID retains activity against T315I after ponatinib failure. MMR is a validated surrogate, but longer follow-up is needed for survival and TFR endpoints.